Table 1 Patient biological and clinical evolution during medical follow-up
From: Persistent parvovirus B19 viremia with chronic arthralgia treated with ascorbic acid: a case report
Date | 20 August 2013 | 22 October 2013 | 11 November 2013 | 31 December 2013 a | 21 January 2014 | 30 January 2014 b | 06 March 2014 |
|---|---|---|---|---|---|---|---|
Month after symptoms onset | 6 | 8 | 10 | 10 | 11 | 11 | 13 |
pvB19-PCRc | + | + | + | + | - | - | - |
pvB19-PCRd CT | 32 | 34 | 38 | 39 | - | - | - |
pvB19-serology IgMe | + | + | + | + | + | + | + |
pvB19-IgM positivity ratio | 6.1 | 6 | 6.77 | 6.7 | 6.5 | NA | 5.9 |
pvB19-serology IgGf | + | + | + | + | + | + | + |
pvB19-IgG positivity ratio | 5.3 | 4.6 | 4.4 | 3.4 | 3.4 | NA | 3.8 |
Analgesic | Ketoprofen | Ketoprofen | Ketoprofen | Ketoprofen | None | None | None |
Visual analog scale (/100) | 30 | 30 | 30 | 30 | 5 | 40 | 10 |